Table 3.

Association Between Durvalumab Treatment Duration and Overall Survival

Variable	Univariate
	HR (95% CI)	p Value
Age	1.04 (0.95–1.14)	0.392
Sex	1.39 (0.31–6.23)	0.665
Histologya	1.15 (0.22–5.96)	0.864
Stage IIIA vs. IIIB/IIIC	0.19 (0.02–1.66)	0.134
Carboplatin vs. cisplatinb	0.36 (0.04–2.99)	0.345
PD-L1 <1% vs. ≥1%	2.59 (0.43–15.57)	0.297
Durvalumab Tx time	0.49 (0.24–1.03)	0.058

CI, confidence interval; HR, hazard ratio; PD-L1, programmed death-ligand 1; Tx, treatment.

^aAdenocarcinoma versus squamous/other.

^bCarboplatin-based versus cisplatin-based chemotherapy regimens.